|
Brief Reports
Citations 381-390 of 1234 total displayed.
|
Past content
(since Jul 1999):
|
Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia
- Elise Chapiro, Lisa Russell, Isabelle Radford-Weiss, Christian Bastard, Michel Lessard, Stephanie Struski, Helene Cave, Sandra Fert-Ferrer, Carole Barin, Odile Maarek, Veronique Della-Valle, Jonathan C. Strefford, Roland Berger, Christine J. Harrison, Olivier A. Bernard, and Florence Nguyen-Khac, the Groupe Francophone de Cytogénétique Hématologique
Blood 2006; 108: 3560-3563.
[Abstract]
[Full text]
[PDF]
Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative
- Maria Luigia Randi, Maria Caterina Putti, Margherita Scapin, Enrica Pacquola, Fabio Tucci, Concetta Micalizzi, Luigi Zanesco, and Fabrizio Fabris
Blood 2006; 108: 3600-3602.
[Abstract]
[Full text]
[PDF]
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
- Craig Kovitz, Hagop Kantarjian, Guillermo Garcia-Manero, Lynne V. Abruzzo, and Jorge Cortes
Blood 2006; 108: 2811-2813.
[Abstract]
[Full text]
[PDF]
Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein
- Marianne Jensby Nielsen, Steen Vang Petersen, Christian Jacobsen, Claus Oxvig, David Rees, Holger Jon Møller, and Søren Kragh Moestrup
Blood 2006; 108: 2846-2849.
[Abstract]
[Full text]
[PDF]
CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities
- Young-Jin Lee, Letetia C. Jones, Nikolai A. Timchenko, Danilo Perrotti, Daniel G. Tenen, and Scott C. Kogan
Blood 2006; 108: 2416-2419.
[Abstract]
[Full text]
[PDF]
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
- Linda M. Scott, Mike A. Scott, Peter J. Campbell, and Anthony R. Green
Blood 2006; 108: 2435-2437.
[Abstract]
[Full text]
[PDF]
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
- Eric Lippert, Marjorie Boissinot, Robert Kralovics, François Girodon, Irène Dobo, Vincent Praloran, Nathalie Boiret-Dupré, Radek C. Skoda, and Sylvie Hermouet
Blood 2006; 108: 1865-1867.
[Abstract]
[Full text]
[PDF]
Frequent antibody production against RAR in both APL mice and patients
- Marie Robin, Juliette Andreu-Gallien, Marie-Helene Schlageter, Djaouida Bengoufa, Isabelle Guillemot, Katerina Pokorna, Carine Robert, Jerome Larghero, Philippe Rousselot, Emmanuel Raffoux, Herve Dombret, Pierre Fenaux, Marika Pla, Dominique Charron, Rose-Ann Padua, and Christine Chomienne
Blood 2006; 108: 1972-1974.
[Abstract]
[Full text]
[PDF]
The epitope recognized by rituximab
- Mascha Binder, Florian Otto, Roland Mertelsmann, Hendrik Veelken, and Martin Trepel
Blood 2006; 108: 1975-1978.
[Abstract]
[Full text]
[PDF]
High molecular response rate of polycythemia vera patients treated with pegylated interferon –2a
- Jean-Jacques Kiladjian, Bruno Cassinat, Pascal Turlure, Nathalie Cambier, Murielle Roussel, Sylvia Bellucci, Marie-Laurence Menot, Gerald Massonnet, Jean-Luc Dutel, Kamel Ghomari, Philippe Rousselot, Marie-Jose Grange, Yasmina Chait, William Vainchenker, Nathalie Parquet, Lina Abdelkader-Aljassem, Jean-François Bernard, Jean-Didier Rain, Sylvie Chevret, Christine Chomienne, and Pierre Fenaux
Blood 2006; 108: 2037-2040.
[Abstract]
[Full text]
[PDF]
|
|
